Market Access Beyond GLP-1Rs: emerging targets poised to gain share of obesity market Pharmaceutical TechnologyNon-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031.Market AccessMetabolic & GLP-1Read full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaceutical Technology Non-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031. Market AccessMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Policy Tracker 2026: Psychedelics get a boostNext: S16 Ep55: OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer Related Stories Market Access NICE aims to cut funding for Amgen lung cancer drug Lumykras pharminent July 9, 2026 Market Access UK, pharma industry pilot rapid access routes for medicines pharminent July 5, 2026 Market Access Medicare GLP-1 Bridge Launches July 1 With $50 Copays pharminent July 3, 2026
